You are here:

bivalirudin (Angiox)

Advice

following a full submission

bivalirudin (Angiox) is accepted for restricted use  within NHS Scotland.

Indication under review: as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.  Bivalirudin should be administered with aspirin and clopidogrel.

Restriction: patients who would have been considered for treatment with heparin in combination with a glycoprotein IIb/IIIa inhibitor.  It should not be used as an alternative to heparin alone.

In patients with STEMI undergoing PCI, bivalirudin, compared with heparin plus a glycoprotein IIb/IIIa inhibitor, was associated with significantly lower rates of major bleeding, cardiac death and thrombocytopenia.
 

Drug Details

Drug Name: bivalirudin (Angiox)
SMC Drug ID: 638/10
Manufacturer: The Medicines Company
Indication: Anticoagulant in adult patients undergoing PCI, including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Restricted
Date Advice Published: 13 September 2010

Back